SeekingAlphaSeptember 4, 2026 at 3:15 AM NY13 hours ago
Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price
Bristol Myers Squibb's growth portfolio now drives nearly 60% of revenue, offsetting legacy drug declines and supporting total revenue growth. See why BMY stock is a Buy.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — SeekingAlpha
Companies in This Story
Related Stories
Which dow jones stocks are moving on Friday?
ChartMill1 hour ago
Exploring the top movers within the S&P500 index during today's session.
ChartMill1 hour ago
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo2 hours ago
Sector Update: Financial
Yahoo3 hours ago
Should You Buy, Sell or Hold PVH Stock Post Q2 Earnings?
Yahoo3 hours ago